IRWDIronwood Pharmaceuticals, Inc.
Is it growing?
Neither accelerating nor breaking down: revenue growing +26% year on year and operating margin widening (+42.3 points), but earnings down −1383% year on year.
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −1% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 53.6% now against 11.3% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is IRWD growing?
Ironwood Pharmaceuticals, Inc. has grown revenue −3.0% a year over three years and −1.2% a year over five, with earnings per share compounding at −46%.
Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · shrinking · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- −1.2%
Revenue growth, 5-year rate · −3.0% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- −46%
Earnings per share, 3-year rate · revenue −3.0% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 17
Years of annual history on file · FY2009 to FY2025, as filed
Details›
- Revenue FY2021
- $414M
- Revenue FY2022
- $411M
- Revenue FY2023
- $443M
- Revenue FY2024
- $351M
- Revenue FY2025
- $296M
Annual income statements as filed with the SEC.
Drug Manufacturers, Specialty & Generic
Ranks #18 of 41 by RyuScore